KeyBanc has commenced coverage on Alignment Healthcare Inc (NASDAQ: ALHC), assigning the company a Sector Weight rating.
The firm acknowledged the potential long-term growth prospects for Alignment Healthcare, citing the company's growth profile, unique value-based care (VBC) strategy, and the management team's confidence in achieving the 2025 EBITDA targets.
Despite the positive outlook, KeyBanc expressed caution due to the complexities surrounding the Medicare Advantage (MA) industry. The firm is looking to observe outcomes from the current concerns over Medicare Star ratings affecting larger peers, the forthcoming third-quarter financial reports indicating higher medical service utilization, and the results of the upcoming election before considering a more bullish stance on the stock.
In other recent news, Alignment Healthcare's earnings and revenue have seen significant growth. The company reported a 47% increase in revenue and a 56% surge in health plan membership.
Stifel has raised its price target for the company to $14.00, following the recognition of Alignment's primary health plan as a 4-star or higher plan on the Centers for Medicare & Medicaid Services (CMS) website. In addition, Baird and TD Cowen have also increased their stock price targets, reflecting confidence in the company's growth outlook.
In terms of corporate changes, Alignment Healthcare has witnessed a reshuffle in its board structure. Board members Thomas Carella and Jeffrey Margolis have resigned, with Margolis entering into a consulting agreement with Alignment Healthcare's primary operating subsidiary. These changes are not attributed to any disagreements regarding company operations, policies, or practices.
These recent developments have led to an upward adjustment in year-end membership expectations by 8,000 members and a forecast of at least 20% growth in 2025. Despite these positive projections, Alignment Healthcare has no plans to enter new states in 2025, focusing instead on profitability and expanding its national footprint.
InvestingPro Insights
Alignment Healthcare's financial metrics and market performance offer additional context to KeyBanc's coverage initiation. According to InvestingPro data, ALHC has demonstrated strong revenue growth, with a 47.34% increase in quarterly revenue as of Q2 2024. This aligns with KeyBanc's recognition of the company's growth profile.
However, the company faces profitability challenges, as highlighted by two InvestingPro Tips: ALHC is not profitable over the last twelve months, and analysts do not anticipate the company will be profitable this year. This may explain KeyBanc's cautious Sector Weight rating despite acknowledging growth potential.
Interestingly, despite these profitability concerns, ALHC has shown impressive market performance. The stock has seen a 134.65% price return over the past six months and a 53.04% return over the last year. This strong performance could reflect investor optimism about the company's long-term prospects, which KeyBanc also noted.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for ALHC, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.